The AI in Business Podcast

Today’s guest is Kandie Ibaka, Vice President and Sanctions Control Officer for International Investigations and Emerging Sanctions in Advisory Controls and Executions at Citi. Kanide joins Emerj Editorial Director Matthew DeMello to discuss how compliance leaders are navigating today’s rapidly shifting regulatory landscape. With global sanctions evolving at an unprecedented pace, Kandie shares how financial institutions are moving beyond basic monitoring to real-time risk interpretation, operational alignment, and strategic response. This episode is sponsored by MindBridge. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1 [http://emerj.com/ad1]. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 [http://emerj.com/expert2] for more information and to be a potential future guest on the ‘AI in Business’ podcast!

In this episode of the ‘AI in Business’ podcast, Deep Srivastav, Chief AI Officer at Franklin Templeton, shares a candid view into the evolving role of AI in wealth and asset management — and how enterprises can move beyond isolated use cases to reshape core business capabilities. Deep unpacks the unique challenges financial firms face when implementing AI, from managing high-stakes accuracy and regulatory demands to harmonizing siloed data systems and building long-term ROI. He outlines Franklin Templeton’s own approach to building a successful AI roadmap, highlighting how cross-functional collaboration and a focus on transforming full business processes — rather than piecemeal experimentation — have proven key to sustained impact. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business’ podcast! This episode is sponsored by FE fundinfo. FE fundinfo is a leading financial data company connecting the investment industry in the UK, Europe and Asia Pacific through a single integrated platform. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

In this episode of the ‘AI in Business’ podcast, Scott Bradley, VP of AI and Innovation at Novartis, returns to discuss how AI is reshaping decision-making at the earliest stages of drug development—and what that means for the future of pharma investment strategy. Host Matthew DeMello and Scott explore how the pharmaceutical industry is transitioning from intuition-led portfolio choices to data-driven precision. They discuss the growing influence of AI in identifying viable drug candidates, designing complex proteins, and even solving long-standing manufacturing challenges. Scott also highlights the impact of AI on shifting portfolio dynamics—enabling pharma companies to target smaller, more specific patient populations and scale up development across a wider range of therapies. With AI now central to everything from molecule discovery to commercialization, the conversation offers a window into how life sciences organizations must adapt both structurally and strategically to stay competitive. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 [https://emerj.com/expert?utm_source=AIB-podcast&utm_medium=site&utm_campaign=promotion] for more information and to be a potential future guest on the ‘AI in Business’ podcast! This episode is sponsored by Intelligencia AI. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1 [http://emerj.com/ad1].

In this episode, Mathew Paruthickal — Global Head of Data Architecture, Utilization, and AI Engineering at Sanofi — joins Emerj Editorial Director Matthew DeMello to explore how AI is reshaping clinical trial operations at scale. He shares how Sanofi is leveraging advanced data strategies to address longstanding bottlenecks in trial design, safety signal detection, and site performance prediction. Mathew outlines the architectural and operational shifts required to move from isolated AI pilots to enterprise-wide transformation. From document intelligence to real-time data orchestration, he details how Sanofi is building integrated, compliant systems that support faster, more informed decision-making across teams and therapeutic areas. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 [https://emerj.com/expert?utm_source=AIB-podcast&utm_medium=site&utm_campaign=promotion] for more information and to be a potential future guest on the ‘AI in Business’ podcast! This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1 [http://emerj.com/ad1].

Today’s guest is Oleg Savin, Enterprise Architect and MES Expert at Unilever. Oleg is a frequent guest speaker at manufacturing conferences worldwide, including this year’s Smart Manufacturing Excellence Summit in Munich. He returns to the program today to discuss use cases in why neurobiological and cybernetic AI capabilities for manufacturers and why it’s imperative for industrial leaders to understand the difference. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business’ podcast! If you’ve enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!